Navigation Links
Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients

KANSAS CITY, Mo.--(BUSINESS WIRE)--May 4, 2007 - New data have demonstrated that relapsing-remitting multiple sclerosis (RRMS) patients treated with COPAXONE(R) (glatiramer acetate injection) following brief immunosuppression with mitoxantrone experienced a 90 percent reduction in magnetic resonance imaging (MRI)-monitored disease activity compared to their baseline. These benefits were achieved early on and were sustained throughout the 24-month study period. These long-term data were consistent with the 15-month initial results of this study, previously presented at an international meeting on multiple sclerosis (MS), which demonstrated that the induction treatment strategy was more effective than COPAXONE(R) alone on reducing relapses and MRI measures of disease activity (p=0.0147). Treatment with COPAXONE(R) after induction with mitoxantrone remained safe and effective throughout the treatment period.

These new findings were presented at the 59th Annual Meeting of the American Academy of Neurology (AAN) along with new confirming MRI findings from the 15-month study, which showed that the decreases in clinical and MRI markers of disease activity, were accompanied by favorable effects on disease burden and irreversible brain tissue damage as shown by significant decreases in the accumulation of lesion load, and significant reduction in the proportion of lesions evolving into chronic black holes.

"This combination therapy is emerging as a promising treatment option for patients who have active RRMS, or who are not responding optimally to traditional first-line therapies," said Tim Vollmer, M.D., Director, Neuroimmunology Program, Barrow Neurological Institute at St. Joseph's Hospital and Medical Center and the primary investigator in this study. "This study builds on earlier studies that demonstrate the effect of COPAXONE(R) on disease activity and inflammation in the central nervous system of RRMS pati
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
2. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
3. Data on Higher Dose of Copaxone and Data Showing Copaxone is Most Cost Effective
4. Data Published in Neurology Showed That Higher Dose of Copaxone Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS)
5. First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone Was More Cost-Effective Than Interferon Beta Therapies for Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
6. Point of Care Strep Tests Speed Treatment, Lower Costs
7. Rapid HIV Testing Increases Possibility of Treatment
8. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
9. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
Post Your Comments:
(Date:7/31/2014)... July 31, 2014  According to data released today ... 2015 average monthly Medicare Part D premium is expected ... than was originally projected, the Pharmaceutical Care Management Association ... continues to be a bright spot in American health ... each region and using cutting edge, cost-saving tools like ...
(Date:7/31/2014)... SAN DIEGO , July 31, 2014  Sorrento Therapeutics, ... death of Mr. Amar Singh , Chief Business Officer ... of apparent natural causes on July 30. "Sorrento ... dear friend and colleague. Our immediate thoughts go to Amar,s ... President and Chief Executive Officer. Mr. Singh ...
(Date:7/31/2014)... -- STAAR Surgical Company (NASDAQ: STAA ) ... and delivery systems for the eye today reported revenue ... $20.0 million, a 10% increase over $18.2 million reported ... currency basis, revenues grew 11% during the second quarter ... The effect of foreign currency exchange reduced sales by ...
Breaking Medicine Technology:Sorrento Announces the Unexpected Death of its Chief Business Officer 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31
... 7 ActivBiotics, Inc. today,announced the results ... effect of rifalazil in the treatment of ... The results demonstrated,that treatment for two months ... in a significant improvement in walking distance,claudication ...
... the American Heart Association Scientific Sessions ... 2007 ... Nabi,Biopharmaceuticals (Nasdaq: NABI ) today announced the successful completion,of ... innovative and proprietary investigational vaccine being,developed to treat nicotine addiction ...
Cached Medicine Technology:Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease 2Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease 3Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 2Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 3Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 4Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 5Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 6Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 7
(Date:7/31/2014)... Leelanau Peninsula, MI (PRWEB) July 31, 2014 ... in preparation of the upcoming harvest. And, to celebrate, folks ... held Saturday and Sunday, September 6 and 7, 2014 along ... weekend festivities is an optional walk or run through the ... & Winery in Suttons Bay. A unique course between rows ...
(Date:7/31/2014)... July 31, 2014 Weblify has finally been ... years of development and testing. The result is a ... in as little as 5 minutes without knowing any HTML ... review , Shane Michaels, an SEO expert, agrees that this ... “I’ve seen a lot of web site builders out there, ...
(Date:7/31/2014)... United Theological Seminary is pleased to ... Donne and Peter J. Bellini. Both began their teaching ... is a Director of Non-Degree Programs, Mark Abbott, who ... Le Donne, Assistant Professor of New Testament, received a ... Testament, Second Temple Judaism, and Greek courses. His research ...
(Date:7/31/2014)... NEWwoodworks, fine woodworking group at ... presence with a website dedicated to highlighting their craft ... specialized in handcrafted cabinetry, furniture, stairs , doors, ... a reputation for taking on the remarkable, challenging projects ... craft with reclaimed wood, often using near extinct species ...
(Date:7/31/2014)... Ticket Down is a dependable source for authentic ... Sun Life Stadium in Miami on Monday, August 4th. ... and diehard soccer fans from the Miami, Florida area are ... Cup final in person at Sun Life Stadium. ... split into two groups where they will then play each ...
Breaking Medicine News(10 mins):Health News:Leelanau Peninsula’s Annual Harvest Stompede Offers a Unique Vineyard Course for Walkers, Runners and Wine Tasters 2Health News:Weblify Review Exposes Ricky Mataka And His New Site Building Platform 2Health News:Weblify Review Exposes Ricky Mataka And His New Site Building Platform 3Health News:Growing Seminary Welcomes New Faculty 2Health News:NEWwoodworks Fine Woodworking Group Launches New Website 2Health News:NEWwoodworks Fine Woodworking Group Launches New Website 3Health News:Guinness International Champions Cup Finals Tickets in Miami, FL Available at Ticket Down 2Health News:Guinness International Champions Cup Finals Tickets in Miami, FL Available at Ticket Down 3
... Hospital Closures and Bankruptcies, PRINCETON, N.J., Nov. ... Association shows that U.S. hospitals enjoyed,healthy profits in ... hospitals,experienced an unprecedented rash of hospital bankruptcies and ... 2009 Edition, released last,week, the nation,s hospitals posted ...
... 2007; Gross Profit Percentage ... Increases from 45% to 50% of Revenue, IDAHO ... INIS) announces financial results for,the third quarter and nine-months ending ... period ended September 30, 2008,was $1,245,164 and $4,429,144 respectively as ...
... N.Y., Nov. 11 Misonix, Inc.,(Nasdaq: MSON ), ... which in Europe is used for the ablation ... today announced plans to,release first quarter fiscal year ... Michael A. McManus, President and Chief,Executive Officer and ...
... provides latest information to medical and investment ... ... of America, Inc.,(CPC) (OTC Bulletin Board: CPCF), today launched its new ... a wealth of information on the company and its investigational,product, MedClose(TM). ...
... colored labels for automated filling of ... sterile anesthesia syringes., ... of colored syringe labels to its Rapid-Fill(TM) Automated,Syringe Filler offering. ... efficient automation for IV syringe filling. The,system reduces pharmacy overhead ...
... and disinfect to minimize spread of germs, OMAHA, Neb., ... family and friends, it may also be a haven for ... Services to help,battle pesky germs before, during and after your ... soapy water. Place antibacterial,hand sanitizer in plain view for guests ...
Cached Medicine News:Health News:Nation's Hospitals Thrive as N.J. Facilities Struggle 2Health News:International Isotopes Inc. Announces Third Quarter and Nine Months 2008 Financial Results 2Health News:International Isotopes Inc. Announces Third Quarter and Nine Months 2008 Financial Results 3Health News:International Isotopes Inc. Announces Third Quarter and Nine Months 2008 Financial Results 4Health News:International Isotopes Inc. Announces Third Quarter and Nine Months 2008 Financial Results 5Health News:International Isotopes Inc. Announces Third Quarter and Nine Months 2008 Financial Results 6Health News:Misonix Schedules First Quarter Fiscal Year 2009 Financial Results Conference Call; November 13, 2008 at 4:30 P.M. Eastern 2Health News:CPC Launches New Web Site Highlighting Medical, Research and Technical Panel, MedClose(TM) VCS Animated Video 2Health News:CPC Launches New Web Site Highlighting Medical, Research and Technical Panel, MedClose(TM) VCS Animated Video 3Health News:Baxa Expands its Automated Syringe Processing Capabilities 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: